Linda Yaccarino, the former chief executive of Elon Musk’s social media platform X, is pivoting into health care.

The digital health company eMed Population Health on Tuesday announced it has appointed Yaccarino as its new CEO. EMed is developing a population health management platform for the blockbuster weight loss and diabetes drugs called GLP-1s, the company said. It had raised a total $22 million as of 2022, according to PitchBook.

Yaccarino, who rose rose to the top of NBCUniversal’s global advertising business before joining X, will help eMed establish “game-changing partnerships” and navigate complex markets, the company said.

“The healthcare industry has been disrupted by technology, but not yet completely transformed by it,” Yaccarino said in a statement. “There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before.”

EMed is part of the growing group of digital health companies that are trying to capitalize on the sky-high demand for GLP-1s. Goldman Sachs analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, and they predict the industry could reach $100 billion in annual revenue by that time.

Yaccarino stepped down from her role as CEO at X in July and did not disclose a reason for her departure. EMed said she is a “highly sought-after leader” with an “undeniable ability to negotiate new partnerships.”

“To be a leader in today’s healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry,” Yaccarino said.

WATCH: Linda Yaccarino steps down as CEO of Elon Musk’s X after two years in the role